Join
Live feed
·
PRReleasevia Quantisnow
Matinas Biopharma Holdings Inc. logo

Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

ByQuantisnow·Wall Street's wire, on your screen.
MTNB· Matinas Biopharma Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MTNB (Matinas Biopharma Holdings Inc.) and more on Quantisnow.